Report Overview

The European Dermatological market is expected to exhibit a CAGR of approximately 7.92% during the forecast period.

The skin and the mucous membranes constitute the main protective interface against the environment. These are highly dynamic organs with crucial biological functions. Dermatological conditions pose a significant threat to patients well-being, mental health, ability to function and social participation. Even though they are not as life threatening as compared to other conditions, they severely impede with the quality of life. These are a plethora of diseases ranging from relatively mild acne to severe cases of Scleroderma. They can be due to allergies, irritants, immune system abnormalities or the genetic makeup of an individual. Out of all the skin conditions, Dermatitis is responsible for the largest global burden of dermatological diseases out of which Atopic Dermatitis holds the highest value in Sweden.



Market Drivers

Dermatological Therapeutics market in Sweden is mainly driven by the increase in prevalence of skin diseases. This is further propelled by the rise in geriatric population who are at an increased risk for dermatological disorders.

There is a general increase in awareness about these conditions which paves the way for early diagnosis which in turn drives the market. Sweden has increased per capita spending on healthcare which boosts market growth.

The market is also driven by innovative new product launches and collaborations among various market players in the development of such products.